John V. Oyler, Founder, Chairman & CEO at BeOne Medicines, shared a post on LinkedIn:
“Today, we announced our Q2 2025 earnings, continuing to build on the momentum from earlier this year.
This quarter marked another strong performance for the company, driven by the dedication and innovation of our BeOne Medicines team.
I’m proud of the consistent progress we’re making as we deliver value for our customers and shareholders. Read the press release here.”
More posts featuring BeOne Medicine on OncoDaily.